HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer.
Combining an epigenetic drug with immunotherapy revived immune responses against small-cell lung cancer in mice, suggesting a testable clinical strategy.
This study shows that the class I HDAC inhibitor entinostat can reprogram the immunosuppressive neuroendocrine phenotype of Myc-driven SCLC, making tumors more susceptible to immune attack by increasing T-cell infiltration and immune checkpoint ligand expression. Combination of entinostat with anti-PD-1 checkpoint blockade achieved significantly improved tumor control and survival in preclinical SCLC mouse models, providing strong mechanistic rationale for clinical trials of this epigenetic-immunotherapy combination.
What the study was
- Study design
- Preclinical in vitro (human SCLC cell lines) + in vivo (RPM mouse allograft model)
- Population
- Myc-driven small cell lung cancer (preclinical; RPM mouse model + human SCLC cell lines)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Molecular Cancer Therapeutics
Why it surfaced
Novel mechanism-driven preclinical combination (epigenetic reprogramming + ICI) in SCLC, a cancer with very limited ICI response; strong in vivo efficacy data but pre-clinical stage only. PROMISING_PRELIMINARY assigned conservatively over NOVEL_TREATMENT pending clinical data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.